Connor Clark & Lunn Investment Management Ltd. Acquires 146,858 Shares of Savara Inc (NASDAQ:SVRA)

Connor Clark & Lunn Investment Management Ltd. grew its holdings in Savara Inc (NASDAQ:SVRA - Free Report) by 21.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 837,467 shares of the company's stock after buying an additional 146,858 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned 0.49% of Savara worth $2,571,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Victory Capital Management Inc. raised its stake in Savara by 7.0% in the 3rd quarter. Victory Capital Management Inc. now owns 140,010 shares of the company's stock valued at $594,000 after acquiring an additional 9,180 shares during the period. Oppenheimer & Co. Inc. increased its holdings in shares of Savara by 14.8% in the third quarter. Oppenheimer & Co. Inc. now owns 115,604 shares of the company's stock valued at $490,000 after purchasing an additional 14,867 shares during the last quarter. LMR Partners LLP raised its holdings in Savara by 138.3% in the 3rd quarter. LMR Partners LLP now owns 36,800 shares of the company's stock valued at $156,000 after acquiring an additional 132,900 shares during the period. Jennison Associates LLC lifted its holdings in Savara by 17.5% during the 3rd quarter. Jennison Associates LLC now owns 6,732,776 shares of the company's stock worth $28,547,000 after purchasing an additional 1,001,296 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in Savara in the 3rd quarter valued at $174,000. 87.93% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. JMP Securities reissued a "market outperform" rating and set a $9.00 target price on shares of Savara in a report on Thursday, December 19th. Wells Fargo & Company started coverage on shares of Savara in a research note on Friday, December 20th. They issued an "overweight" rating and a $8.00 price objective for the company. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Savara currently has an average rating of "Moderate Buy" and an average price target of $8.83.

Savara Price Performance

SVRA stock traded down $0.04 during midday trading on Friday, reaching $2.82. The company had a trading volume of 4,781,511 shares, compared to its average volume of 1,279,005. Savara Inc has a 1-year low of $1.58 and a 1-year high of $5.34. The stock has a 50 day moving average price of $2.73 and a 200-day moving average price of $3.33. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The company has a market capitalization of $483.97 million, a price-to-earnings ratio of -6.56 and a beta of 0.60.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.